Compare Sun Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TTK HEALTHCARE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA TTK HEALTHCARE SUN PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 78.2 10.6 737.9% View Chart
P/BV x 3.3 1.5 216.8% View Chart
Dividend Yield % 0.6 1.0 63.5%  

Financials

 SUN PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
TTK HEALTHCARE
Mar-19
SUN PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4841,215 39.8%   
Low Rs315610 51.7%   
Sales per share (Unadj.) Rs136.9444.4 30.8%  
Earnings per share (Unadj.) Rs17.517.2 101.2%  
Cash flow per share (Unadj.) Rs26.027.6 94.1%  
Dividends per share (Unadj.) Rs4.005.00 80.0%  
Dividend yield (eoy) %1.00.5 182.7%  
Book value per share (Unadj.) Rs188.7177.9 106.0%  
Shares outstanding (eoy) m2,399.2614.13 16,979.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.1 142.2%   
Avg P/E ratio x22.952.9 43.3%  
P/CF ratio (eoy) x15.433.0 46.5%  
Price / Book Value ratio x2.15.1 41.3%  
Dividend payout %22.929.0 79.1%   
Avg Mkt Cap Rs m958,86412,894 7,436.3%   
No. of employees `00017.82.3 768.1%   
Total wages/salary Rs m63,6241,307 4,867.9%   
Avg. sales/employee Rs Th18,490.62,715.7 680.9%   
Avg. wages/employee Rs Th3,582.6565.3 633.7%   
Avg. net profit/employee Rs Th2,357.6105.4 2,236.6%   
INCOME DATA
Net Sales Rs m328,3756,279 5,229.9%  
Other income Rs m6,36078 8,206.2%   
Total revenues Rs m334,7356,356 5,266.2%   
Gross profit Rs m69,898496 14,103.6%  
Depreciation Rs m20,528147 13,993.0%   
Interest Rs m3,02734 8,956.5%   
Profit before tax Rs m52,702393 13,423.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,6060-   
Tax Rs m8,228149 5,525.9%   
Profit after tax Rs m41,868244 17,180.1%  
Gross profit margin %21.37.9 269.7%  
Effective tax rate %15.637.9 41.2%   
Net profit margin %12.83.9 328.5%  
BALANCE SHEET DATA
Current assets Rs m316,5422,717 11,649.6%   
Current liabilities Rs m157,0641,571 9,999.0%   
Net working cap to sales %48.618.3 266.0%  
Current ratio x2.01.7 116.5%  
Inventory Days Days8832 272.2%  
Debtors Days Days10547 224.5%  
Net fixed assets Rs m243,102991 24,531.0%   
Share capital Rs m2,399141 1,698.0%   
"Free" reserves Rs m450,2452,373 18,973.8%   
Net worth Rs m452,6452,514 18,002.8%   
Long term debt Rs m20,2893 596,741.2%   
Total assets Rs m682,5254,158 16,414.3%  
Interest coverage x18.412.6 145.9%   
Debt to equity ratio x00 3,314.7%  
Sales to assets ratio x0.51.5 31.9%   
Return on assets %6.66.7 98.6%  
Return on equity %9.29.7 95.4%  
Return on capital %11.216.9 66.3%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m74,219225 32,956.8%   
Fx outflow Rs m27,96471 39,324.8%   
Net fx Rs m46,255154 30,018.0%   
CASH FLOW
From Operations Rs m65,548173 37,867.0%  
From Investments Rs m-25,88897 -26,827.4%  
From Financial Activity Rs m-57,151-307 18,597.9%  
Net Cashflow Rs m-13,857-38 36,755.7%  

Share Holding

Indian Promoters % 63.7 65.4 97.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 3.7 138.6%  
FIIs % 23.0 5.2 442.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 25.8 32.2%  
Shareholders   133,026 12,723 1,045.6%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WOCKHARDT  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 71.7% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS